Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 17Carcinoma, Hepatocellular 5Recurrence 4Neoplasms, Plasma Cell 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Liver Neoplasms 3Sarcoma 2NSCLC 2Lymphoma, Large B-Cell, Diffuse 2Esophageal Neoplasms 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Leiomyosarcoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Glioblastoma 1Extrapancreatic Neuroendocrine Tumor 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Extrapancreatic Neuroendocrine Tumor × Thalidomide × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡